SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-196027"
 

Search: id:"swepub:oai:DiVA.org:uu-196027" > Assessment of glyce...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Schneck, Karen B. (author)

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study : application of a semi-mechanistic, integrated glucose-insulin-glucagon model

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2012-12-22
  • Springer Science and Business Media LLC,2013
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-196027
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-196027URI
  • https://doi.org/10.1007/s10928-012-9287-8DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • A proof of concept study was conducted to investigate the safety and tolerability of a novel oral glucokinase activator, LY2599506, during multiple dose administration to healthy volunteers and subjects with Type 2 diabetes mellitus (T2DM). To analyze the study data, a previously established semi-mechanistic integrated glucose-insulin model [1-5] was extended to include characterization of glucagon dynamics. The model captured endogenous glucose and insulin dynamics, including the amplifying effects of glucose on insulin production and of insulin on glucose elimination, as well as the inhibitory influence of glucose and insulin on hepatic glucose production. The hepatic glucose production in the model was increased by glucagon and glucagon production was inhibited by elevated glucose concentrations. The contribution of exogenous factors to glycemic response, such as ingestion of carbohydrates in meals, was also included in the model. The effect of LY2599506 on glucose homeostasis in subjects with T2DM was investigated by linking a one-compartment, pharmacokinetic model to the semi-mechanistic, integrated glucose-insulin-glucagon system. Drug effects were included on pancreatic insulin secretion and hepatic glucose production. The relationships between LY2599506, glucose, insulin, and glucagon concentrations were described quantitatively and consequently, the improved understanding of the drug-response system could be used to support further clinical study planning during drug development, such as dose selection.

Subject headings and genre

  • Glucokinase activator
  • LY2599506
  • Pharmacokinetics
  • Pharmacodynamics
  • Semi-mechanistic
  • Glucose-insulin-glucagon model
  • Diabetes mellitus

Added entries (persons, corporate bodies, meetings, titles ...)

  • Zhang, Xin (author)
  • Bauer, Robert (author)
  • Karlsson, Mats O.Uppsala universitet,Institutionen för farmaceutisk biovetenskap(Swepub:uu)matskarl (author)
  • Sinha, Vikram P. (author)
  • Uppsala universitetInstitutionen för farmaceutisk biovetenskap (creator_code:org_t)

Related titles

  • In:Journal of Pharmacokinetics and Pharmacodynamics: Springer Science and Business Media LLC40:1, s. 67-801567-567X1573-8744

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view